Cartalax

Cartalax — Research Use Only Cartalax is a synthetic tripeptide with the sequence Ala-Glu-Asp (AED). It belongs to the class of short regulatory peptides, often called peptide bioregulators, described in research associated with V. Kh. Khavinson and colleagues. Laboratory research has examined Cartalax mainly in cell-culture models, including cartilage- and connective-tissue cells and aging fibroblast cultures, with readouts such as proliferation, apoptosis, and gene-expression markers. Most available findings come from in-vitro and animal studies, largely from a single research group, and should not be interpreted as established human safety or therapeutic efficacy. Product Information Product: Cartalax Sequence: Ala-Glu-Asp (AED) Total content: 20 mg Compound type: Synthetic short peptide Length: 3 amino acids Form: Lyophilized research material Purity: Refer to the product-specific Certificate of Analysis Storage: Store according to the supplied handling documentation Research Applications Cartalax is commonly investigated in connection with: Short-peptide bioregulator research Chondrocyte and connective-tissue cell models Fibroblast cellular-aging models Proliferation and apoptosis markers Gene-expression changes in cultured cells Important Notice This product is sold exclusively for laboratory research and analytical purposes. It is not a drug, dietary supplement, food, cosmetic, or medical product. FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT FOR HUMAN CONSUMPTION. This product is not intended to diagnose, treat, cure, mitigate, or prevent any disease. No dosing, administration, joint, cartilage, anti-aging, or therapeutic guidance is provided. Purchasers are responsible for ensuring that possession, handling, and research activities comply with all applicable laws, regulations, and institutional requirements.